Shenzhen YHLO Biotech CoSHSE:688575 +2.59%64 Days Payable is 121.23 as of Mar. 2026, which is 48% above its 10-year median of 82.03. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥14.55 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks better than 73.37% on this metric.
The historical rank and industry rank for Shenzhen YHLO Biotech Co's Days Payable or its related term are showing as below:
SHSE:688575'
s Days Payable Range Over the Past 10 Years
Min: 49.77 Med: 82.03 Max: 145.06
Current: 127.45
During the past 9 years, Shenzhen YHLO Biotech Co's highest Days Payable was 145.06. The lowest was 49.77. And the median was 82.03.
SHSE:688575's Days Payable is ranked better than 73.37% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs SHSE:688575: 127.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688575 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Shenzhen YHLO Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co (SHSE:688575) has a Days Payable of 121.23 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shenzhen YHLO Biotech Co and its competitors. This is 48% above median its historical median of 82.03. Over the past decade, Shenzhen YHLO Biotech Co's Days Payable has ranged from 49.77 to 145.06. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #212 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 26.6%.
Is Shenzhen YHLO Biotech Co's Days Payable too high?
Shenzhen YHLO Biotech Co's current Days Payable of 121.23 is 48% above median its 10-year median of 82.03. Over the past 10 years, this metric has ranged from a low of 49.77 to a high of 145.06. The Medical Devices & Instruments industry median Days Payable is 67.97. Shenzhen YHLO Biotech Co's value of 121.23 is 78.4% above this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #212 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #212 out of 796 companies for Days Payable. This puts Shenzhen YHLO Biotech Co in the upper half of its industry. The industry median Days Payable is 67.97. Shenzhen YHLO Biotech Co's value of 121.23 is 78.4% above this benchmark. Historically, Shenzhen YHLO Biotech Co's own Days Payable has ranged from 49.77 to 145.06 over the past decade. While the company's 10-year median is 82.03 vs. the industry median of 67.97, Shenzhen YHLO Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current Days Payable of 121.23 is 78.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shenzhen YHLO Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current Days Payable is 121.23, which is 48% above median its own 10-year median of 82.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.55, compared to a current price of ¥9.11 — trading 37.4% below its estimated fair value. The current Days Payable is 121.23, which is 48% above median its 10-year median of 82.03 and 78.4% above the Medical Devices & Instruments industry median of 67.97. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current Days Payable is 121.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥9.11 is trading 37.4% below its estimated GF Value™ of ¥14.55.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
Days Payable: 121.23 (48% above median its 10-year median of 82.03)
GF Value™: ¥14.55 vs. price of ¥9.11 (37.4% below fair value)
Industry Position: 78.4% above the Medical Devices & Instruments median (#212 of 796)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
